Teliso-V FDA Approval Status
Last updated by Judith Stewart, BPharm on Oct 30, 2024.
FDA Approved: No
Brand name: Teliso-V
Generic name: telisotuzumab vedotin
Company: AbbVie Inc.
Treatment for: Non Small Cell Lung Cancer
Teliso-V (telisotuzumab vedotin) is a first-in-class, c-Met protein directed antibody-drug conjugate (ADC) in development for the treatment of non-small cell lung cancer (NSCLC).
- The c-Met protein is a receptor tyrosine kinase that can be overexpressed in many solid tumors, including NSCLC.
- Teliso-V works by targeting c-Met protein in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous NSCLC with c-Met protein overexpression.
Development timeline for Teliso-V
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.